iShares J.P. Morgan $ EM Corp Bond UCITS ETF USD (Acc) is a bonds ETF from iShares tracking the J.P. Morgan $ EM Corp Bond index through physical replication. Domiciled in Ireland and launched in 2018, the fund manages about 1.7 bn € and charges a TER of 0.50% — 50 € per year on a €10,000 investment. Income is automatically reinvested in the fund (accumulating).
iShares J.P. Morgan $ EM Corp Bond UCITS ETF USD (Acc) competes with 2 other products on the same index (J.P. Morgan $ EM Corp Bond): it ranks 1st by fund size and 1st by ongoing cost, with a TER of 0.50% against a group median of 0.50%. It has been listed since 2018, 8 years of track record.
On a €10,000 investment the TER costs 50 € a year, and no product in the group costs less.
Replication is physical: the fund holds the underlying securities directly. The ten largest positions account for 5.2% of the portfolio.
Income is accumulated: no distribution is paid out, the share price absorbs it. In a savings plan this removes the need to reinvest dividends by hand. The fund is denominated in USD. That is not the same as currency risk: the exposure comes from the currencies of the underlying holdings, not from the denomination or the trading currency of a given listing.
The fund is domiciled in Ireland, which determines the tax treatment of income received by the fund and the supervisory authority.
| Gaz Capital S.A. 4.95% | 0.8% |
| Teva Pharmaceutical Finance Netherlands III B.V. 3.15% | 0.6% |
| Altice Financing S.A. 7.5% | 0.5% |
| Saudi Arabian Oil Company 4.25% | 0.5% |
| Saudi Arabian Oil Company 4.38% | 0.5% |
| Teva Pharmaceutical Finance Netherlands III B.V. 2.8% | 0.5% |
| Saudi Arabian Oil Company 3.5% | 0.5% |
| Ecopetrol S.A. 6.88% | 0.5% |
| Ecopetrol S.A. 5.88% | 0.4% |
| Sands China Ltd 5.4% | 0.4% |
| London Stock Exchange | EMCA | USD |
Source: the fund's KID and the issuer's official documentation — data verified as of July 2026.
This page is informational and is not an investment recommendation. Figures may contain errors or be out of date: always check the KID and the issuer's factsheet before any decision.